PACIFIC BIOSCIENCES OF CALIF (PACB)
US69404D1081 - Common Stock
Overall PACB gets a fundamental rating of 2 out of 10. We evaluated PACB against 58 industry peers in the Life Sciences Tools & Services industry. PACB may be in some trouble as it scores bad on both profitability and health. PACB shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
In the past year PACB has reported negative net income.
PACB had a negative operating cash flow in the past year.
PACB had negative earnings in 4 of the past 5 years.
PACB had negative operating cash flow in 4 of the past 5 years.
1.2 Ratios
PACB has a Return On Assets of -17.57%. This is in the lower half of the industry: PACB underperforms 65.52% of its industry peers.
PACB has a Return On Equity of -43.74%. This is in the lower half of the industry: PACB underperforms 72.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.57% | ||
| ROE | -43.74% | ||
| ROIC | N/A |
ROA(3y)-14.79%
ROA(5y)-18.82%
ROE(3y)-40.82%
ROE(5y)-53.38%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 28.04%, PACB is doing worse than 77.59% of the companies in the same industry.
In the last couple of years the Gross Margin of PACB has declined.
The Profit Margin and Operating Margin are not available for PACB so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.04% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-12.13%
GM growth 5Y-2.57%
2. Health
2.1 Basic Checks
PACB does not have a ROIC to compare to the WACC, probably because it is not profitable.
PACB has more shares outstanding than it did 1 year ago.
PACB has more shares outstanding than it did 5 years ago.
PACB has a worse debt/assets ratio than last year.
2.2 Solvency
PACB has an Altman-Z score of -1.28. This is a bad value and indicates that PACB is not financially healthy and even has some risk of bankruptcy.
PACB's Altman-Z score of -1.28 is on the low side compared to the rest of the industry. PACB is outperformed by 79.31% of its industry peers.
PACB has a Debt/Equity ratio of 1.27. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of PACB (1.27) is worse than 81.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.28 |
ROIC/WACCN/A
WACC6.2%
2.3 Liquidity
PACB has a Current Ratio of 7.81. This indicates that PACB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 7.81, PACB belongs to the best of the industry, outperforming 86.21% of the companies in the same industry.
A Quick Ratio of 7.21 indicates that PACB has no problem at all paying its short term obligations.
PACB's Quick ratio of 7.21 is amongst the best of the industry. PACB outperforms 84.48% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.81 | ||
| Quick Ratio | 7.21 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 13.57% over the past year.
PACB shows a strong growth in Revenue. In the last year, the Revenue has grown by 56.29%.
PACB shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 20.60% yearly.
EPS 1Y (TTM)13.57%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q16.22%
Revenue 1Y (TTM)56.29%
Revenue growth 3Y36.47%
Revenue growth 5Y20.6%
Revenue growth Q2Q113.37%
3.2 Future
Based on estimates for the next years, PACB will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.90% on average per year.
Based on estimates for the next years, PACB will show a very strong growth in Revenue. The Revenue will grow by 35.47% on average per year.
EPS Next Y12.89%
EPS Next 2Y13.07%
EPS Next 3Y15.87%
EPS Next 5Y17.9%
Revenue Next Year19.79%
Revenue Next 2Y32.04%
Revenue Next 3Y34.06%
Revenue Next 5Y35.47%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for PACB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PACB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as PACB's earnings are expected to grow with 15.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.07%
EPS Next 3Y15.87%
5. Dividend
5.1 Amount
PACB does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PACIFIC BIOSCIENCES OF CALIF
NASDAQ:PACB (4/29/2024, 7:18:47 PM)
Premarket: 1.67 +0.07 (+4.37%)1.6
+0.13 (+8.84%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap428.72M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.57% | ||
| ROE | -43.74% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 28.04% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.11
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.27 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 7.81 | ||
| Quick Ratio | 7.21 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)13.57%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y12.89%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)56.29%
Revenue growth 3Y36.47%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y